Evidence map›Paper›PMID 37519466›Full record

ReviewBiological psychiatry global open science2023

Illness Phase as a Key Assessment and Intervention Window for Psychosis.

Christian G Kohler, Daniel H Wolf, Anissa Abi-Dargham, Alan Anticevic, Youngsun T Cho, Clara Fonteneau, Roberto Gil, Ragy R Girgis, David L Gray, Jack Grinband and 13 more

Open access · goldAbstract readReview
In one paragraph

Review in Biological psychiatry global open science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Personality domains in early stages of psychosis: a systematic review and meta-analysis.European archives of psychiatry and clinical neuroscience · 2026
    Pooled it
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 1 country.

Christian G KohlerDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Daniel H WolfDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Anissa Abi-DarghamDepartment of Psychiatry and Behavioral Health, Renaissance School of Medicine, Stony Brook University, Stony Brook.
Alan AnticevicDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
Youngsun T ChoDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
Clara FonteneauDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
Roberto GilDepartment of Psychiatry and Behavioral Health, Renaissance School of Medicine, Stony Brook University, Stony Brook.
Ragy R GirgisDepartments of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York.
David L GrayCerevel Therapeutics Research and Development, East Cambridge, Massachusetts.
Jack GrinbandDepartments of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York.
Jonathan A JavitchDepartments of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York.
Joshua T KantrowitzDepartments of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York.
John H KrystalDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
Jeffrey A LiebermanDepartments of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York.
John D MurrayDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
Mohini RanganathanDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
Nicole SantamauroDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
Jared X Van SnellenbergDepartment of Psychiatry and Behavioral Health, Renaissance School of Medicine, Stony Brook University, Stony Brook.
Zailyn TamayoDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
TRANSCENDS Group
Ruben C GurDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Raquel E GurDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Monica E CalkinsDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Yale University · USUniversity of Pennsylvania · USColumbia University · USStony Brook University · USCerevel Therapeutics (United States) · USNathan Kline Institute for Psychiatric Research · USNew York Psychoanalytic Society and Institute · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
A Translational and Neurocomputational Evaluation of a D1R Partial Agonist for SchizophreniaU01MH121766 · NIMH · YALE UNIVERSITY · PI KRYSTAL, JOHN H. · 2019 to 2022
$11.8M
NCATS NIH HHS UL1 TR001863NIMH NIH HHS U01 MH121766
6 · The paper itself

Abstract

The phenotype of schizophrenia, regardless of etiology, represents the most studied psychotic disorder with respect to neurobiology and distinct phases of illness. The early phase of illness represents a unique opportunity to provide effective and individualized interventions that can alter illness trajectories. Developmental age and illness stage, including temporal variation in neurobiology, can be targeted to develop phase-specific clinical assessment, biomarkers, and interventions. We review an earlier model whereby an initial glutamate signaling deficit progresses through different phases of allostatic adaptation, moving from potentially reversible functional abnormalities associated with early psychosis and working memory dysfunction, and ending with difficult-to-reverse structural changes after chronic illness. We integrate this model with evidence of dopaminergic abnormalities, including cortical D

Identifiers

PMID37519466
PMCPMC10382701
OpenAlexW4283073763

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.